Search





Search





Markets
/
Stocks
/
rnaz
/

Transcode Therapeutics Inc

RNAZ

Add to Watchlist

4.750USD

-0.500-9.52%

Close 07-31 16:00（ET）Quotes delayed by 15 min

3.96MMarket Cap

LossP/E TTM

Transcode Therapeutics Inc

4.750

-0.500-9.52%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

RNAZ Cash Flow Statement

You can access the annual and quarterly cash flow statements of Transcode Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-60.75%-4.98M

-158.78%-8.14M

-4.36%-4.08M

-79.26%-4.19M

21.35%-3.10M

44.45%-3.15M

-11.60%-3.91M

46.72%-2.34M

12.77%-3.94M

-40.89%-5.66M

20.72%-3.51M

-30.23%-4.39M

-14.31%-4.51M

-151.11%-4.02M

-44.13%-4.42M

---3.37M

---3.95M

---1.60M

---3.07M

Net income from continuing operations

-47.16%-17.79M

-127.23%-13.44M

-109.19%-4.86M

17.61%-4.28M

-263.27%-12.09M

-44.73%-5.92M

56.20%-2.32M

-19.56%-5.19M

30.94%-3.33M

20.38%-4.09M

-23.55%-5.30M

7.06%-4.34M

-38.81%-4.82M

-83.41%-5.13M

-84.13%-4.29M

---4.67M

---3.47M

---2.80M

---2.33M

Operating gains losses

-53.23%23.94K

-63.55%44.78K

-96.25%4.78K

-90.59%13.44K

-63.87%51.17K

-12.35%122.86K

-8.11%127.52K

3.81%142.83K

41.37%141.65K

375.08%140.17K

459.56%138.78K

506.18%137.59K

363.86%100.20K

1.78%29.50K

229.16%24.80K

--22.70K

--21.60K

--28.99K

--7.54K

Deferred tax

--231.31K

--226.07K

----

Other non-cash items

--10.31M

779.96%5.25M

-100.00%0.00

----

450.10%596.96K

3.65%111.49K

3.62%110.48K

55.17%109.48K

561.03%108.52K

--107.56K

--106.62K

--70.56K

87.58%-23.54K

100.00%0.00

--0.00

---189.55K

---31.40K

Change in working capital

564.97%2.12M

-87.92%113.87K

118.44%354.61K

-114.35%-224.50K

51.34%-455.12K

146.50%942.35K

-252.27%-1.92M

530.88%1.56M

-2205.20%-935.21K

-307.24%-2.03M

580.57%1.26M

-130.83%-363.12K

107.92%44.42K

-25.75%977.81K

66.30%-262.82K

--1.18M

---560.67K

--1.32M

---779.80K

-Change in receivables

----

---638.00

----

-Change in prepaid expenses

-637.29%-695.66K

106.06%911.82K

-48.08%-1.03M

-39.88%462.01K

215.09%129.47K

90.21%442.50K

-15.48%-692.90K

-45.25%768.48K

83.29%-112.50K

-3.35%232.64K

67.46%-600.02K

5.18%1.40M

-641.83%-673.21K

-69.84%240.71K

17.82%-1.84M

--1.33M

--124.25K

--798.07K

---2.24M

-Change in payables and accrued expense

993.93%1.77M

-107.48%-43.15K

222.67%1.40M

-204.01%-944.69K

71.01%-198.46K

127.62%576.68K

-158.37%-1.14M

152.10%908.30K

-218.84%-684.49K

-442.55%-2.09M

-3.69%1.96M

-1329.90%-1.74M

184.96%575.98K

17.45%609.45K

35.64%2.03M

---121.93K

---677.93K

--518.91K

--1.50M

-Change in other current assets

----

--0.00

--111.86K

----

--0.00

---111.86K

----

-Change in other current liabilities

435.57%85.26K

-100.00%0.00

--0.00

6.09%-25.41K

193.24%25.41K

100.00%0.00

-100.00%0.00

---27.06K

---27.25K

---27.44K

--81.75K

100.00%0.00

--0.00

----

--0.00

---6.99K

--0.00

---35.69K

Cash from non-recurring investing activities

Cash from operating activities

-60.75%-4.98M

-158.78%-8.14M

-4.36%-4.08M

-79.26%-4.19M

21.35%-3.10M

44.45%-3.15M

-11.60%-3.91M

46.72%-2.34M

12.77%-3.94M

-40.89%-5.66M

20.72%-3.51M

-30.23%-4.39M

-14.31%-4.51M

-151.11%-4.02M

-44.13%-4.42M

---3.37M

---3.95M

---1.60M

---3.07M

Investing cash flow

Net cash from continuing investing activities

----

1232.00%6.66K

----

--500.00

179.42%12.87K

-74.84%4.55K

-70.25%3.84K

-100.00%0.00

--4.61K

-56.94%18.11K

-57.93%12.90K

-65.89%28.21K

-100.00%0.00

--42.05K

--30.66K

--82.73K

--71.55K

Capital expenditures

----

1232.00%6.66K

----

--500.00

179.42%12.87K

-74.84%4.55K

-70.25%3.84K

-100.00%0.00

--4.61K

-56.94%18.11K

-57.93%12.90K

-67.09%28.21K

-100.00%0.00

--42.05K

--30.66K

--85.73K

--71.55K

Net cash flow from disposal of fixed assets

----

1232.00%6.66K

----

--500.00

179.42%12.87K

-74.84%4.55K

-70.25%3.84K

-100.00%0.00

--4.61K

-56.94%18.11K

-57.93%12.90K

-65.89%28.21K

-100.00%0.00

--42.05K

--30.66K

--82.73K

--71.55K

Net cash flow from business transactions

----

--2.22K

----

Cash from non-current investing activities

Net cash flow from investing activities

----

-787.20%-4.44K

----

---500.00

-179.42%-12.87K

74.84%-4.55K

70.25%-3.84K

100.00%0.00

---4.61K

56.94%-18.11K

57.93%-12.90K

65.89%-28.21K

100.00%0.00

---42.05K

---30.66K

---82.73K

---71.55K

Financing cash flow

Cash flow from continuous financing activities

----

226.52%23.12M

-118.63%-455.73K

-100.00%0.00

45.47%8.85M

624.02%7.08M

-66.89%2.45M

-87.65%785.20K

415.56%6.09M

333.16%978.15K

3372.94%7.39M

--6.36M

19614.24%1.18M

2280.78%225.82K

-100.88%-225.82K

--0.00

--5.99K

--9.48K

--25.56M

Net cash flow from debt Issuance/repayment

----

--0.00

Net cash flow from common stock issuance/repurchase

----

-100.00%1.00

-100.00%0.00

45.47%8.85M

624.02%7.08M

-66.27%2.45M

-87.91%785.20K

415.56%6.09M

--978.15K

--7.26M

--6.50M

--1.18M

-100.00%0.00

----

--9.48K

--26.34M

Net cash flow from preferred stock issuance/repurchase

----

--22.67M

----

Proceeds from stock option exercised by employees

----

--0.00

-100.00%0.00

--0.00

--5.99K

----

Net cash flow from other financing activities

----

--455.73K

---455.73K

----

160.14%135.80K

---135.80K

----

--225.82K

70.87%-225.82K

----

--0.00

---775.28K

Net cash from non-recurrent financing activities

Net cash from financing activities

----

226.52%23.12M

-118.63%-455.73K

-100.00%0.00

45.47%8.85M

624.02%7.08M

-66.89%2.45M

-87.65%785.20K

415.56%6.09M

333.16%978.15K

3372.94%7.39M

--6.36M

19614.24%1.18M

2280.78%225.82K

-100.88%-225.82K

--0.00

--5.99K

--9.48K

--25.56M

Net cash flow

Beginning cash balance

206.54%17.81M

51.18%2.84M

119.85%7.37M

135.45%11.57M

109.97%5.81M

-74.83%1.88M

-6.10%3.35M

202.82%4.91M

-44.30%2.77M

-15.22%7.45M

-73.42%3.57M

-90.37%1.62M

-76.14%4.97M

-60.93%8.79M

16789.40%13.44M

--16.85M

--20.83M

--22.50M

--79.57K

Current period cash flow changes

-186.45%-4.98M

280.61%14.98M

-206.95%-4.54M

-169.02%-4.19M

168.31%5.76M

183.99%3.94M

-138.11%-1.48M

-179.96%-1.56M

164.14%2.15M

-22.58%-4.69M

183.49%3.88M

157.11%1.95M

15.79%-3.35M

-128.32%-3.82M

-120.73%-4.65M

---3.41M

---3.97M

---1.67M

--22.42M

Ending cash balance

10.95%12.84M

206.54%17.81M

51.18%2.84M

119.85%7.37M

135.45%11.57M

109.97%5.81M

-74.83%1.88M

-6.10%3.35M

202.82%4.91M

-44.30%2.77M

-15.22%7.45M

-73.42%3.57M

-90.37%1.62M

-76.14%4.97M

-60.93%8.79M

--13.44M

--16.85M

--20.83M

--22.50M

Free cash flow

----

-158.95%-8.15M

----

44.44%-3.15M

-11.82%-3.93M

46.84%-2.34M

12.93%-3.94M

-39.91%-5.66M

20.62%-3.51M

-29.16%-4.41M

-13.75%-4.53M

-140.02%-4.05M

-40.85%-4.42M

---3.41M

---3.98M

---1.69M

---3.14M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Transcode Therapeutics Inc Generate?



Transcode Therapeutics Inc generated -19.52M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Transcode Therapeutics Inc's Operating Cash Flow Change Year Over Year?



Transcode Therapeutics Inc's operating cash flow increased by -46.34% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Transcode Therapeutics Inc Spend on Capital Expenditures?



Transcode Therapeutics Inc spent 6.66K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Transcode Therapeutics Inc's Financing Cash Flow Changed?



Transcode Therapeutics Inc used 31.52M in financing activities in the latest quarter.

What is free cash flow and why does it matter for RNAZ?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Transcode Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -19.52M reflecting a -46.15% change from the previous year.